AD severity is associated with incremental societal costs in Sweden.

According to a new study, topical calcineurin inhibitors such as pimecrolimus and tacrolimus did not increase risk in AD patients.

Over one third of pediatric patients with HS did not meet all three major diagnostic criteria at the time of diagnosis.

Patients with HS who report feelings of stigmatization from their condition had worse QoL and higher levels of depression.

A recent study has shown that AD and bacterial skin infection rates are higher in Indigenous youth compared to non-Indigenous youth.

Adult and pediatric AD patients have experienced more adverse effects after prolonged use of corticosteroids.

Tralokinumab treatment in patients with AD does not increase Covid-19 severity or interfere with Covid-19 vaccinations.

A digitally delivered intervention showed significant improvements in treatment adherence and other clinical outcomes in AD patients.